R837 is an immune modulator with no in vitro activity against herpes simplex virus (HSV). We evaluated topical R837 as therapy for genital HSV type 2 infection using the guinea pig model of this disease. Furthermore, we investigated the effect of R837 therapy on acute and latent neural HSV infections. Therapy initiated 12 h after viral inoculation and given twice a day significantly reduced the acute neural infection so that HSV was recovered from only 1 of 64 neural tissue specimens obtained from R837 recipients compared with 43 of 56 specimens obtained from placebo recipients (P < 0.0001). R837 initiated 36 h after HSV inoculation and given once a day also significantly reduced the total mean lesion score of the acute disease from 14.1 ± 4.3 to 2.6 ± 5.3 (P < 0.0001) and shortened the period of vaginal HSV shedding from 6.9 ± 1.7 to 3.2 --1.4 days (P < 0.001). R837-treated animals also developed fewer HSV recurrences than did controls (2.0 ± 1.7 versus 5.1 ± 1.7; P < 0.0002). Latent HSV was detected in 23 of 24 dorsal root ganglia explant cultures from placebo recipients but in only 2 of 30 cultures from R837-treated animals, and HSV in these 2 cultures was detectable only with the addition of a demethylating agent. Topical R837 exhibited in vivo anti-HSV activity, reducing both acute and latent neural infections as well as acute and recurrent genital disease.
R837 is an immune modulator with no in vitro activity against herpes simplex virus (HSV). We evaluated topical R837 as therapy for genital HSV type 2 infection using the guinea pig model of this disease. Furthermore, we investigated the effect of R837 therapy on acute and latent neural HSV infections. Therapy initiated 12 h after viral inoculation and given twice a day significantly reduced the acute neural infection so that HSV was recovered from only 1 of 64 neural tissue specimens obtained from R837 recipients compared with 43 of 56 specimens obtained from placebo recipients (P < 0.0001). R837 initiated 36 h after HSV inoculation and given once a day also significantly reduced the total mean lesion score of the acute disease from 14.1 ± 4.3 to 2.6 ± 5.3 (P < 0.0001) and shortened the period of vaginal HSV shedding from 6.9 ± 1.7 to 3.2 --1.4 days (P < 0.001). R837-treated animals also developed fewer HSV recurrences than did controls (2.0 ± 1.7 versus 5.1 ± 1.7; P < 0.0002). Latent HSV was detected in 23 of 24 dorsal root ganglia explant cultures from placebo recipients but in only 2 of 30 cultures from R837-treated animals, and HSV in these 2 cultures was detectable only with the addition of a demethylating agent. Topical R837 exhibited in vivo anti-HSV activity, reducing both acute and latent neural infections as well as acute and recurrent genital disease.
Therapy for herpes simplex virus (HSV) infections should moderate the acute phase of disease, the development of latency, and the frequency of recurrences. Most antiviral agents modify the acute phase of clinical disease but have no effect on latent virus unless therapy is initiated within a few hours of HSV inoculation (13, 14, 17, 18, 23) . For example, in the guinea pig model of genital HSV type 2 (HSV-2) infection, acyclovir decreased the initial disease incidence but did not alter the establishment of latency or recurrence rates, even when therapy was initiated within 12 h of HSV-2 inoculation (4). In contrast, we have observed significant decreases in both detectable latent virus and genital recurrences after administration of topical R837 was begun 12 h after HSV-2 inoculation (16).
R837 is a biologic response modifier that has no in vitro anti-HSV activity (16) . R837 induces interferon when administered either intraperitoneally (8) or intravaginally (16) and enhances HSV-specific lymphocyte proliferation, interleukin-2 production, and delayed hypersensitivity but not antibody production (16) . Because the decreased recurrence rate that we previously observed could have been due to persisting up-regulation of cell-mediated immunity, decreased neural HSV-2 levels, or both, we examined the effects of R837 therapy administered as described previously (16) on the magnitude of initial neural infection and sought latent virus by methods which increase the in vitro reactivation of latent virus (2) .
In previous studies, R837 administered twice a day at 10 mg/kg per day induced fever, weight loss, and decreased water intake. In addition, 35% of R837-treated animals had less than 36 h of vaginal virus replication, developed no HSV-specific immune response, and were not protected against subsequent intravaginal HSV-2 rechallenge (16). We therefore also evaluated once-a-day therapy at 5 mg/kg per dose that was initiated 36 h after viral inoculation. Both the * Corresponding author. toxicity and efficacy against acute, recurrent, and latent HSV-2 disease were determined.
MATERIALS AND METHODS
Drug. R837 {1-(2-methyl propyl)-1H-imidazo [4,5-c] quinolin 4-amine} was provided by 3M Riker, 3M Health Care Group (St. Paul, Minn.) as a 1% suspension for intravaginal administration. Drug was administered intravaginally by syringe, with the excess being smeared on genital skin. The vehicle without R837 was administered as the placebo.
Cells and virus. First-through third-passage rabbit kidney (RK) cell monolayers were prepared from 3-week-old Pasteurella-free, female New Zealand White rabbits (Hazelton, Denver, Pa.) as reported previously (4) . HSV-2 strain 333 (16) was prepared as clarified supernatants from RK cells 24 h after infection at a multiplicity of infection of 1 and was maintained frozen at -70°C.
Experimental design. Hartley female guinea pigs (weight, 400 to 500 g; Charles River Breeding Laboratories, Inc., Wilmington, Mass.) were used. Animals were inoculated intravaginally with either 5 x 105 PFU of strain 333 HSV-2 (16) or the same volume of clarified supernatant from uninfected RK cells. In experiments in which we explored acute neural infection, drug (total dose, 10 mg/kg per day) or placebo was applied every 12 h for 5 days beginning 12 h after the intravaginal inoculation of HSV-2, as described previously (16) . Five to six animals per day were then sacrificed from the placebo and treatment groups on days 3 through 5 after HSV-2 inoculation. Lumbosacral dorsal root ganglia and spinal cords were removed, minced, and divided into two parts. Half was inoculated immediately as minced tissue onto duplicate cultures of RK cells, and the other half was frozen immediately at -70°C. The frozen half was later thawed, homogenized in 1.0 ml of minimal essential medium, and centrifuged; and the titer of the supernatant was determined in duplicate to quantitate virus (3). Minced explants were observed for cytopathic effect for 10 days, while the 1512 BERNSTEIN AND HARRISON titration dishes were stained with crystal violet after 72 h of incubation at 37°C. Vaginal virus excretion was quantitated from animals from days 1 to 5 as described previously (4) .
To evaluate delayed once-a-day therapy, animals were randomly divided into four groups: sham-inoculated placebo recipients (n = 15), sham-inoculated R837 recipients (n = 20), HSV-2-inoculated placebo recipients (n = 20), and HSV-2-inoculated R837 recipients (n = 20). One control animal and three animals in the R837 treatment group were not infected following HSV-2 inoculation (they shed virus for <24 h) and were not included in the analysis. Another R837-treated animal shed virus only on days 1 to 3, did not develop HSV antibody, and was also excluded from analysis of clinical and virologic data.
In the modified regimen, R837 (at a dose of 5 mg/kg) or placebo was applied once a day for 5 days beginning 36 h after HSV-2 inoculation. Animals were bled serially by intracardiac puncture for determination of antibody titers and interferon levels. Daily weight and temperatures (16) were determined for 28 days. The acute genital disease was quantitated by using a skin lesion scoring system ranging from 0 to 4 as described previously (4, 26) . The total lesion score is the sum of the daily scores from days 1 to 14 (4) . Recurrent disease was evaluated from day 15, when the acute disease had resolved, until day 60 (4, 16, 26 (Fig. 1) . Treated animals developed a mean peak lesion score + standard deviation (SD) of 0.8 ± 1.2 compared with a mean peak lesion score ± SD of 3.7 ± 0.8 in placebo-treated animals (P < 0.0001). Similarly, the total mean lesion score ± SD was reduced from 14.1 ± 4.3 to 2.6 ± 5.3 in R837-treated animals (P < 0.0001).
Vaginal HSV shedding was similar in treated and placebo recipients up to the time of R837 administration, but the geometric mean titer (GMT) was approximately 1 log1o unit lower within 24 h of the initiation of R837 therapy (day 3 after inoculation) (Fig. 2) . Therapy also shortened the duration of vaginal virus shedding from 6.9 ± 1.7 to 3.2 ± 1.4 days (P < 0.001).
Daily administration of topical R837 at a dose of 5 mg/kg to sham-infected animals resulted in minimal weight loss (mean, 8.0 g on day 5 of treatment) and mild fever (mean, 0.7°C on day 2 of treatment) compared with the weight loss and fever in sham-infected placebo recipients (Fig. 3) . Weight loss and temperature elevations were less in HSV-2-infected R837 recipients than in HSV-2-infected placebo recipients.
Effect of delayed R837 therapy on immune response. By delaying R837 therapy for 36 h, all but one infected animal (infection being defined as vaginal virus shedding for >24 h) developed anti-HSV antibody. This one animal shed HSV-2 only on days 1 to 3 following inoculation. Although R837-treated animals developed HSV antibody, the GMT was significantly lower on day 28 in treated animals than it was in control animals (log2 GMT, 6.4 ± 1.0 versus 7.7 ± 0.6, respectively; P <0.001).
As reported previously (16), topical R837 induced high levels of interferon circulating in plasma in both HSVinfected and uninfected animals. The interferon concentrations ± standard errors (expressed as human alpha inter- Effect of delayed R.837 therapy on latent and recurrent infections. Recurrent genital di'sease was also reduced by administration of R837 even at the reduced daily dose that was begun 36 h after H{SV-2 inoculation. R837 recipients developed 2.0 ± 1.7 recurrent episodes compared with 5.1 ± 1.7 in placebo recipients (P < 0.0002). The number of days with recurrent lesions was also reduced from 8.1 + 3.6 to 3.1 + 2.3 (P <'0.0001).
Latent HSV-2 was detected in the dorsal root ganglia of 1 of 10 R837-treated animals (both HMBA-treated cultures from a single animal) and was detected in the dorsal root ganglia of 8 of 8 placebo-treated animals (23 of 24 cultures; P <0.001) ( Table 3) . Lat'ent virus was also detected in 4 of 30 spinal cord explant cultures from 3 of 10 R837-treated animals (all from HMBA-treated cultures) and in 10 of 24 cultures (P < 0.03) from 6 of 8 placebo-treated animals.
Thus, HMBA treatment of explants was necessary to detect latent HSV in R837-treated but not placebo-treated animals.
DISCUSSION
We have previously observed that topical R837 given twice daily beginning 12 h after HSV inoculation completely protects guinea pigs from acute HSV-2 genital infection and almost completely eliminates recurrent HSV disease (16) . We hypothesized that this potent immune modulator may alter subsequent recurrent disease by the continued upregulation 'of the immune'system or by decreasing latent neural HSV-2 levels. In this evaluation HSV was recovered during the acute phase of the infection from the neural tissue of only 1 of 16 R837-treated animals and only at the minimal detectable level, suggesting that the reduced recurrence pattern which we observed previously (16) was a consequence of a reduced neural infection. R837 therapy, which was initiated at 12 h (16) or 36 h after HSV inoculation, also reduced the number of animals in which latent virus could be detected. Both of these effects could have resulted from limiting the initial viral replication in the genital tract, and thus decreasing the quantity of virus that reached the ganglia, or by limiting HSV replication within the ganglia. In addition, persistent R837-induced immune enhancement could also contribute to the reduced frequency of recurrences. Future experiments are needed to determine whether R837 therapy initiated after latency has been established can reduce recurrent disease.
Demethylating agents such as HMBA (2) enhance the recovery of latent HSV from ganglia and spinal cords. Indeed, isolates from R837-treated animals were recovered only from tissues that were explanted in the presence of HMBA. Even with the addition of HMBA, however, latent virus was detected' in only 3 of 10 treated animals, although 7 animals manifested recurrent disease. HMBA also shortened the time for recovery of latent virus, so that HSV was detected by day 8 in all explant dorsal root ganglia from untreated animals and by day 10 in the two cultures from R837-treated animals; by standard techniques (24, 26) , the time to HSV detection is approximately 14 to 28 days.
We have previously reported that R837-treated animals with less than 36 h of vaginal replication do not develop an immune response to HSV and are susceptible to intravaginal rechallenge with HSV-2 (16). In the experiment reported here, less frequent dosing beginning 36 h after viral inoculation not only reduced acute and recurrent genital disease but also allowed animals to develop immune responses to HSV, which would be expected to provide protection from reinoculation (4, 25) . Although only data regarding the antibody response are presented, we have also performed assays on cell-mediated immunity which revealed HSV-specific immune responses in treated animals that were not diminished compared with the immune responses in controls (C. J. Harrison and D. I. Bernstein, manuscript in preparation). A reduction in the dose of R837 also reduced the fever and weight loss induced by the higher dose.
This modified regimen still markedly affected the course of the HSV infection and induced high levels of interferon. Acute clinical disease was significantly reduced, although protection was no longer complete. Vaginal virus shedding was also significantly reduced beginning 24 h after the initiation of therapy (Fig. 2) at a rate equivalent to that observed when therapy was begun earlier (16) ( Table 2) . Similarly, the delayed and decreased dose reduced recurrent disease, but to a lesser extent than earlier and higher dosing did. Since HSV enters peripheral nerves and infects dorsal root ganglia at about 2 to 3 days after genital inoculation of guinea pigs (3, 26) , it is not surprising that delayed therapy was somewhat less effective in reducing recurrences than was treatment that was begun prior to ganglionic involvement. It appeared, however, that therapy that was begun even 36 h after viral inoculation decreased latent infection, because we observed significant differences in the recovery of latent virus from R837 recipients versus that from placebo recipients, and latent virus was only recovered from R837 recipients when HMBA was added to the explant culture.
It appears that R837 may be more effective than previously studied immune modulators for the treatment of genital HSV infections. For example poly(rI) (rC12u) reduced the level of clinical disease when it was given before or 20 h after HSV-2 inoculation of guinea pigs but was ineffective when it was given 48 h postinoculation, and the titers of HSV in the ganglia of treated animals were not significantly different from those in the ganglia of control animals (1) . Alpha interferon (human) was also effective in guinea pigs when it was given prophylactically or shortly (0.5 h) after inoculation but not at 24 h after inoculation with HSV type 1 (15) . Similarly, alpha interferon (11, 12) and inosine pranobex, an immune modifier (21, 22) , have been disappointing for the treatment of genital HSV infections in humans. When muramyl tripeptide-phosphatidylethanolamine, another biologic response modifier, was evaluated in the guinea pig model of genital herpes infection, only moderate effects were seen, even when it was given prophylactically (10) . While the results of these studies cannot be compared directly because of the different experimental systems used in each one, only R837 therapy affected clinical disease, vaginal viral shedding, and latency.
In this trial, once-a-day topical R837 therapy initiated 36 h after viral inoculation more effectively reduced clinical disease and viral replications than did previous trials with oral acyclovir begun 12 h after viral inoculation of guinea pigs (4). Furthermore, even delayed R837 therapy significantly reduced recurrent disease and the recovery of latent virus, whereas acyclovir does not (4) . Similarly, although acyclovir therapy can modify acute HSV disease in humans (6, 20) , its effects on the subsequent recurrence pattern are ill defined (7, 9, 19) . Further evaluation of topical R837 as possible therapy for genital HSV-2 disease in humans appears warranted.
